[Clinical studies on imipenem/cilastatin sodium in perinatal use].
The clinical efficacy and the safety of imipenem/cilastatin sodium (IPM/CS) in perinatal infections were studied. The results are summarized below. 1. Clinical efficacy was evaluated in 12 patients with intrauterine infections (endometritis), 3 patients with amniotic fluid infections, 2 patients with puerperal fever and 3 patients with other infections. The drug was administered by intravenous drip infusion at a 0.5g to 1.0g dose as IPM and the total doses during an entire course of treatment were 1.5g to 15g. 2. Clinical efficacies were excellent in 4 (20%) and good in 16 patients (80%) and the efficacy rate was 100%. Ten patients had not improved upon treatments with other previous antibiotics. 3. Infective bacteria were eradicated in 4, decreased in 1, and replaced in 6 patients. 4. No side effects or abnormal clinical laboratory test values were observed in any patient.
Chimura
T
T
Department of Obstetrics and Gynecology, School of Medicine, Yamagata University.
Morisaki
N
N
Hirayama
T
T
Matsuo
M
M
D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin / Q000008:administration & dosage* / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D004716:Endometritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D011645:Puerperal Infection / Q000188:drug therapy*
D015377:Cilastatin; D015378:Imipenem